40 Recruiting Clear Cell Renal Cell Carcinoma Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Clear Cell Renal Cell Carcinoma
Related Conditions
Top Recruiting Clear Cell Renal Cell Carcinoma Studies
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
📍 Fairbanks Memorial Hospital — Fairbanks, Alaska
View Study & Checklist ➔Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
📍 USC / Norris Comprehensive Cancer Center — Los Angeles, California
View Study & Checklist ➔Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
📍 City of Hope Comprehensive Cancer Center — Duarte, California
View Study & Checklist ➔A Phase 1/2 Trial of ADI-270 in ccRCC
📍 Adicet Clinical Trials — Redwood City, California
View Study & Checklist ➔Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
📍 University of Iowa Hospitals & Clinics — Iowa City, Iowa
View Study & Checklist ➔Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
📍 The University of Kansas Cancer Center — Westwood, Kansas
View Study & Checklist ➔Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
📍 University of South Alabama Mitchell Cancer Institute — Mobile, Alabama
View Study & Checklist ➔A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
📍 Local Institution — Chicago, Illinois
View Study & Checklist ➔Prior Axitinib as a Determinant of Outcome of Renal Surgery
📍 UC San Diego Moores Cancer Center — La Jolla, California
View Study & Checklist ➔Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
📍 Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
View Study & Checklist ➔Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
📍 Los Angeles County-USC Medical Center — Los Angeles, California
View Study & Checklist ➔Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
📍 UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
View Study & Checklist ➔Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
📍 Xencor Investigative Site — Phoenix, Arizona
View Study & Checklist ➔A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
📍 Research Site — Birmingham, Alabama
View Study & Checklist ➔Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
📍 University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
View Study & Checklist ➔Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
📍 Cancer Center at Saint Joseph's — Phoenix, Arizona
View Study & Checklist ➔Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
📍 The University of Texas M. D. Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma
📍 Research site — Omaha, Nebraska
View Study & Checklist ➔Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
📍 The University of Texas M. D. Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
📍 NEO-811 Los Angeles Site — Duarte, California
View Study & Checklist ➔Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
View Study & Checklist ➔Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
📍 UT MD Anderson — Houston, Texas
View Study & Checklist ➔